Company Adagene Inc.

Equities

ADAG

US0053291078

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
2.6 ^USD	+1.96%		+16.59%	+34.62%

Mar. 29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 29	Adagene Inc. Announces Board Changes	CI

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Companyâs main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Number of employees: 174

USD in Million	2022	Weight	2023	Weight	Delta
Monoclonal Antibody Drugs 100.0 %	9	100.0 %	18	100.0 %	+94.90%

USD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	9	100.0 %	18	100.0 %	+94.90%

Managers	Title	Age	Since
Peizhi Luo CEO	Chief Executive Officer	59	11-02-24
Man Kin Tam DFI	Director of Finance/CFO	47	19-08-31
JC Xu CTO	Chief Tech/Sci/R&D Officer	60	20-07-31
Xiao Hong She CTO	Chief Tech/Sci/R&D Officer	58	11-10-31
Yan Li CTO	Chief Tech/Sci/R&D Officer	50	11-10-31
Fang Yong Du CTO	Chief Tech/Sci/R&D Officer	55	11-12-31
Ami Knoefler IRC	Investor Relations Contact	-	21-06-30
Chunfang Gu PRN	Corporate Officer/Principal	-	17-08-31
Ling Zhou HRO	Human Resources Officer	-	19-09-30
Dana Hu-Lowe PRN	Corporate Officer/Principal	-	21-10-31

Members of the board	Title	Age	Since
Peizhi Luo CEO	Chief Executive Officer	59	11-02-24
Mervyn Turner BRD	Director/Board Member	77	23-04-27
Cuong Viet Do BRD	Director/Board Member	58	22-11-20
Fang Yong Du CTO	Chief Tech/Sci/R&D Officer	55	11-12-31
Man Kin Tam DFI	Director of Finance/CFO	47	19-08-31
Yumeng Wang BRD	Director/Board Member	33	23-04-27
Yiu Leung Cheung BRD	Director/Board Member	64	21-02-07
Min Li BRD	Director/Board Member	62	21-02-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	55,145,839	52,504,353 ( 95.21 %)	0	95.21 %

Name	Equities	%	Valuation
6 Dimensions Capital 9.020 %	3,982,902	9.020 %	9 M $
FIL Ltd. (Subfiler) 8.707 %	3,844,836	8.707 %	9 M $
Impresa Management LLC 3.055 %	1,348,985	3.055 %	3 M $
Hongshan 3.042 %	1,343,364	3.042 %	3 M $
Artal Group SA 2.310 %	1,020,000	2.310 %	2 M $
General Atlantic LLC 0.5979 %	264,000	0.5979 %	620 400 $
Barclays Bank Plc 0.3966 %	175,130	0.3966 %	411 556 $
Exome Asset Management LLC 0.3519 %	155,383	0.3519 %	365 150 $
Morgan Stanley Capital Services LLC 0.1940 %	85,677	0.1940 %	201 341 $
Prelude Capital Management LLC 0.0648 %	28,620	0.0648 %	67 257 $

Name	Equities	%	Valuation
Peizhi Luo 21.37 %	11,622,853	21.37 %	22 M $
GP Capital Co. Ltd. 9.818 %	5,340,742	9.818 %	10 M $
Eight Roads Principal Investments 8.872 %	4,826,037	8.872 %	9 M $
General Atlantic LLC 8.792 %	4,782,441	8.792 %	9 M $
Impresa Management LLC 8.516 %	4,632,237	8.516 %	9 M $
Panacea Venture 5.055 %	2,750,000	5.055 %	5 M $
Fang Yong Du 2.185 %	1,188,444	2.185 %	2 M $

Adagene, Inc.

Suzhou Industrial Park No. 218 Xingh Street

215123, Suzhou

+86 512 8777 3632

http://www.adagene.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.55 USD

Average target price

5 USD

Spread / Average Target

+96.08%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ADAGENE INC.	+34.62%	113M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs